What the data shows
The emergence of the Cicada COVID variant BA.3.2 raises critical questions regarding its implications for public health and immunity. Is this variant capable of evading the protections offered by vaccines and previous infections? The answer appears to be yes, as BA.3.2 has been identified as a highly mutated variant that may evade immunity from both vaccines and prior infections.
BA.3.2, first identified in South Africa in November 2024, has since made its way to the United States, where it was detected in a traveler returning from the Netherlands in June 2025. As of February 11, 2026, this variant has been reported in at least 25 states across the U.S., indicating a significant spread. Notably, BA.3.2 possesses between 70 to 75 mutations in its spike protein, setting it apart from other variants and potentially altering how it interacts with the immune system.
Symptoms associated with BA.3.2 include common respiratory issues such as cough, fever, sore throat, and shortness of breath, along with loss of smell or taste, fatigue, headache, and gastrointestinal symptoms like diarrhea or vomiting. Despite its extensive mutations, health experts have noted that BA.3.2 is not causing more severe disease or hospitalizations compared to previous variants. Dr. Robert H. Hopkins Jr. stated, “I have not seen any data which indicates that Cicada is any more severe than other circulating variants,” providing some reassurance to the public.
Vaccination continues to play a crucial role in mitigating the impact of BA.3.2. Experts like Andrew Pekosz emphasize that the function of vaccines is to prevent severe illness, stating, “Vaccination is still going to help limit cases.” Current vaccines are expected to provide protection against severe disease stemming from this variant, even as it raises concerns about infection rates.
As of early February, BA.3.2 accounted for approximately 30% of COVID-19 infections in some Eastern European countries, highlighting its growing prevalence. In the U.S., wastewater samples have also detected BA.3.2 at 132 sites, further underscoring its spread within communities.
The background of BA.3.2 reveals that it emerged over a year ago and gradually increased in prevalence, particularly in the fall of 2025. However, the exact reasons for its resurgence remain unclear, and the long-term impact of BA.3.2 on COVID-19 infection rates is still uncertain. Details remain unconfirmed, leaving health officials and the public with questions about the future trajectory of this variant.
In summary, the Cicada COVID variant BA.3.2 presents a complex challenge for public health officials as they navigate its implications for immunity and disease severity. Continuous monitoring and vaccination efforts will be essential in managing its spread and protecting vulnerable populations.
